Shilpa Asks Court for Novartis’s Gilenya Profits, Citing Patent

Shilpa said the active ingredient in Gilenya, Novartis’s blockbuster multiple-sclerosis drug, is made using a process covered by a Shilpa patent issued in 2016.

• Shilpa is seeking damages including cash compensation for actual loss, Novartis’s “profits unjustly obtained, reasonable royalties, and exemplary damages for infringement,” according to complaint filed Tuesday in federal court in Wilmington, Delaware
  • Shilpa also wants a court order blocking U.S. sales of Gilenya until patent has expired, complaint says
• Patent covers polymorphic forms of fingolimod and processes for making them
• Gilenya’s active ingredient is fingolimod hydrochloride; Shilpa said in complaint that Novartis knows it’s a ...